Covid-19 roundup: US ne­go­ti­at­ing for more dos­es of Pfiz­er vac­cine; Brazil de­lays ef­fi­ca­cy read­out for Sino­vac vac­cine

5 years ago
Coronavirus

Eli Lil­ly picks up gene ther­a­py play­er Pre­vail in deal worth $1B+, mak­ing good on bolt-on pledge from ear­li­er this ...

5 years ago
Deals
Cell/Gene Tx

Bob Nelsen ex­its board and pres­i­dent steps down at Uni­ty as fall­out from the an­ti-ag­ing biotech's PhII miss con­tin­ues

5 years ago
People
Pharma

Sanofi, No­vo back a small biotech that's neck and neck with Pfiz­er to de­vel­op a Group B strep­to­coc­cus vac­cine

5 years ago
Financing

Ab­b­Vie pulls the trig­ger on a Covid-19 an­ti­body, go­ing all in on a drug dis­cov­ered by re­search al­liance

5 years ago
R&D

FDA slaps a hold on a star Re­gen­eron can­cer drug, paus­ing tri­al en­roll­ment as cy­tokine storms trig­ger new tox tem­pest

5 years ago
FDA+

At­tor­neys gen­er­al ask HHS to pun­ish 340B pro­gram bilk­ers — but phar­ma claims it's fight­ing 'waste and abuse'

5 years ago
Pharma

Go­ing to Chi­na? ADC Ther­a­peu­tics spot­lights a new way to do it with Hill­house-backed Over­land

5 years ago
Deals
China

News brief­ing: Arv­inas shares dou­ble on in­ter­im da­ta for two can­cer pro­grams; UK bio­phar­ma snaps up on­col­o­gy CRO

5 years ago
News Briefing

Sarep­ta shakes up C-suite as they pre­pare to test FDA on Duchenne again

5 years ago
People

No­vo Hold­ings in­vests in Hemab, a com­pa­ny go­ing against the he­mo­phil­ia gene ther­a­py grain with a plan for bis­pecifics

5 years ago
Deals
Cell/Gene Tx

CRISPR up­start ticks off an­oth­er box on the IPO prep list as RA, SVB Leerink step in on a mega-raise

5 years ago
Financing
Bioregnum

Got­tlieb op-ed: Man­u­fac­tur­ers need to ramp up pro­duc­tion of an­ti­bod­ies as 'Covid in­sur­ance pol­i­cy'

5 years ago
Coronavirus
Manufacturing

Mass­Bio head Cough­lin set to step down af­ter over­see­ing mas­sive bio­phar­ma ex­pan­sion in the state dur­ing 13-year ...

5 years ago
People
R&D

Chas­ing Am­gen on KRAS com­bo, Roche dish­es out $75M for Re­lay's SHP2 drug to pair with in-house pro­gram

5 years ago
Deals

Covid-19 roundup: Trump walks back plans to pri­or­i­tize White House staff for vac­cine; As­traZeneca drops sub­group of ...

5 years ago
Coronavirus

Af­ter scor­ing big Pfiz­er buy­out, a Ther­a­chon co-founder turns once again to dwarfism with $24M Se­ries A

5 years ago
Financing
R&D

In an end-of-year sur­prise, As­traZeneca nabs rare dis­ease stal­wart Alex­ion in $39B buy­out. But why?

5 years ago
Deals

FDA au­tho­rizes Pfiz­er-BioN­Tech Covid-19 vac­cine

5 years ago
Coronavirus

Trump of­fi­cials dou­ble up on Mod­er­na vac­cine sup­ply, eye­ing H1 mR­NA cam­paign as Big Phar­mas stum­ble

5 years ago
Coronavirus

A Covid-19 vac­cine OK is im­mi­nent, but Trump con­tin­ues un­prece­dent­ed as­sault on the FDA

5 years ago
Coronavirus

Glob­al Blood Ther­a­peu­tics re­cruits a CHOP sick­le cell ex­pert as R&D chief; Catal­ent plucks Janssen vet to head new ...

5 years ago
Peer Review

News brief­ing: CG On­col­o­gy nets $47M Se­ries D for blad­der can­cer stud­ies; Sin­gle-cell tran­scrip­tom­ic start­up rais­es ...

5 years ago
News Briefing

Vi­a­tris plans across-the-board cuts that could en­dan­ger 9,000 work­ers, 15 plants in post-merg­er re­struc­tur­ing scheme

5 years ago
Pharma
First page Previous page 766767768769770771772 Next page Last page
A service from the Financial Times